The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast cancer.
Denise A. Yardley
No relevant relationships to disclose
Ahmad Awada
No relevant relationships to disclose
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Eisai; Novartis; Roche
Howard A. Burris
No relevant relationships to disclose
Amy C. Peterson
Employment or Leadership Position - Medivation
Consultant or Advisory Role - Medivation
Iulia Cristina Tudor
Employment or Leadership Position - Medivation
Stock Ownership - Medivation
Shanna Stopatschinskaja
Employment or Leadership Position - Medivation
Joyce Leta Steinberg
Employment or Leadership Position - Astellas Pharma
Luca Gianni
Consultant or Advisory Role - AstraZeneca; BioScience; Boehringer Ingelheim; Celgene; Genentech; GlaxoSmithKline; Novartis; Pfizer; Roche; Taiho Pharmaceutical
Kathy D. Miller
No relevant relationships to disclose
Eric P. Winer
No relevant relationships to disclose